SAN CARLOS, Calif., April 6, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing and non-invasive prenatal testing (NIPT) today announced an ...

SAN CARLOS, Calif. & DALLAS--(BUSINESS WIRE)--Natera, a leading innovator in prenatal genetic testing, today announced the initiation of a distribution partnership with ProPath, a wholly ...

SAN CARLOS, Calif., Oct. 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that the company's ...

SAN CARLOS, Calif., Jan. 29, 2018 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will feature its recently expanded ...

SAN CARLOS, Calif., Aug. 22, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has now processed more than two million Panorama® ...

When discussing the value of screening for 22q, the authors concluded that, “the PPV of cfDNA for 22q11.2DS is higher and the false positive rate is lower than that associated with other accepted ...

Natera, a leading innovator in prenatal genetic testing, announced today that data demonstrating the accuracy of its non-invasive prenatal screening test, Panorama™, in detection of multiple sex ...

TAMPA (FOX 13) - Every mother wants their newborn to be healthy, but not every pregnancy is risk-free. There is a new prenatal test helping to find abnormalities as early as nine weeks into pregnancy.

Natera (San Carlos, California) has completed a $54.6 million financing round to support the expansion and continued global rollout of its non-invasive prenatal test, Panorama. The test uses fetal ...

Study aligns with Natera's longstanding commitment to generate robust, real-world clinical evidence and highlights unique capabilities of Panorama SNP-based NIPT In this study, from a pool of 18,984 ...